ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2014

Aug 19, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD RESEARCH CORP (ARWR)
CIK: 0000879407
Period of Report: 2014-08-15

Reporting Person: Myszkowski Kenneth Allen (CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-08-15	Common Stock	M	15000	$5.19	Acquired	86500	Direct
2014-08-15	Common Stock	M	25000	$7.00	Acquired	111500	Direct
2014-08-15	Common Stock	S	40000	$14.0215	Disposed	71500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-08-15	Stock Option (right to buy)	$5.19	M	15000	Disposed	2022-02-16	Common Stock (15000)	Direct
2014-08-15	Stock Option (right to buy)	$7.00	M	25000	Disposed	2019-11-16	Common Stock (25000)	Direct

Footnotes

F1: Represents the weighted average price at which shares were sold within a range between 14.00 and 14.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

F3: Represents first vesting date. Option vests over four years from date of grant.